Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K

Cancer Prevention Research

Volumn 4, Issue 4, 2011, Pages 582-591

  Kim, Jong Eun ^a,b   Lee, Dong Eun ^a,b   Lee, Ki Won ^a,c   Son, Joe Eun ^a   Seo, Sang Kwon ^a   Li, Jixia ^b   Jung, Sung Keun ^a,b   Heo, Yong Seok ^c   Mottamal, Madhusoodanan ^b   Bode, Ann M ^b   Dong, Zigang ^b   Lee, Hyong Joo ^a  

^a Seoul National University   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; ISORHAMNETIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P90; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKIN CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; FEMALE; FLAVONOLS; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE 1; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955796192     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0032     Document Type: Article

References (48)

1. Ridky TW. Nonmelanoma skin cancer. J Am Acad Dermatol 2007;57:484-501. (Pubitemid 47239135)
2. Lee DA, Miller SJ. Nonmelanoma skin cancer. Facial Plast Surg Clin North Am 2009;17:309-24.
3. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol 2007;4:462-9.
4. Gordon LG, Scuffham PA, Van Der Pols JC, McBride P, Williams GM, Green AC. Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol 2009; 129:2766-71.
5. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150:194-8.
6. Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006;54:933-46.
7. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16. (Pubitemid 43199589)
8. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16. (Pubitemid 44036456)
9. El-Abaseri TB, Hansen LA. EGFR activation and ultraviolet light-induced skin carcinogenesis. J Biomed Biotechnol 2007;2007:97939.
10. Rittie L, Kansra S, Stoll SW, Li Y, Gudjonsson JE, Shao Y, et al. Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin. Am J Pathol 2007;170:2089-99. (Pubitemid 47339281)
11. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437. (Pubitemid 39096597)
12. Chun K-S, Surh Y-J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004;68:1089-100. (Pubitemid 39099277)
13. Repasky GA, Zhou Y, Morita S, Der CJ. Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling. Mol Carcinog 2007;46:958-70.
14. Suomela JP, Ahotupa M, Yang B, Vasankari T, Kallio H. Absorption of flavonols derived from sea buckthorn (Hippophae rhamnoides L.) and their effect on emerging risk factors for cardiovascular disease in humans. J Agric Food Chem 2006;54:7364-9. (Pubitemid 44554964)
15. Ma G, Yang C, Qu Y, Wei H, Zhang T, Zhang N. The flavonoid component isorhamnetin in vitro inhibits proliferation and induces apoptosis in Eca-109 cells. Chem-Biol Interact 2007;167:153-60. (Pubitemid 46498021)
16. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metast Rev 2010;29:405-34.
17. Lee SK, Kwon BM, Baek NI, Kim SH, Lee JH, Park HW, et al. Anti-proliferation effects of isorhamnetin isolated from Persicaria thunbergii on cancer cell lines. Nat Prod Sci 2006;12:214-6. (Pubitemid 46141031)
18. Steffen Y, Gruber C, Schewe T, Sies H. Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 2008;469:209-19. (Pubitemid 50008450)
19. Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 2007;28:1918-27. (Pubitemid 47500604)
20. Choi KH, Kim JE, Song NR, Son JE, Hwang MK, Byun S, et al. Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res 2010;85:836-44.
21. Horton HM, Hernandez P, Parker SE, Barnhart KM. Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice. Cancer Res 1999;59:4064-8. (Pubitemid 29393578)
22. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006;59:51-64. (Pubitemid 43903278)
23. Huang C, Ma WY, Dong Z. Requirement for phosphatidylinositol 3- kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P? cells. Mol Cell Biol 1996;16:6427-35. (Pubitemid 26361001)
24. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192-7.
25. Walker EH, Perisic O, Ried C, Stephens L, Williams RL. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 1999;402:313-20. (Pubitemid 129516270)
26. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 2000;6:909-19.
27. Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37Suppl 4:S9-15.
28. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995;269:234-8.
29. Suzukawa K, Weber TJ, Colburn NH. AP-1, NFkB, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environ Health Perspect 2002;110:865-70.
30. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91:609-13. (Pubitemid 24041451)
31. Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumour promoter induces anchorage independence irreversibly. Nature 1979;281:589-91. (Pubitemid 10242874)
32. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54. (Pubitemid 35204731)
33. Bae YS, Kang SW, Seo MS, Baines IC, Tckle E, Chock PB, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem 1997;272:217-21. (Pubitemid 27021147)
34. Ullrich A, Coussens L, Hayflick JS. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-25. (Pubitemid 14102443)
35. Pennington JAT. Food composition databases for bioactive food components. J Food Compost Anal 2002;15:419-34.
36. Morand C, Crespy V, Manach C, Besson C, Demigne C, Remesy C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol 1998;275:R212-9.
37. Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 1999;65:337-53. (Pubitemid 29325278)
38. Williams RJ, Spencer JPE, Rice-Evans C. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 2004;36:838-49.
39. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7. (Pubitemid 36019639)
40. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
41. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. New Engl J Med 2007;356:2131-42. (Pubitemid 47010839)
42. Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One 2007;2:e1279.
43. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999;5:810-6. (Pubitemid 29318616)
44. Kang NJ, Lee KW, Rogozin EA, Cho Y-Y, Heo Y-S, Bode AM, et al. Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/ p90RSK/activator protein-1 pathway. J Biol Chem 2007;282:32856-66. (Pubitemid 350159319)
45. Huang C, Ma WY, Yound MR, Colburn N, Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci U S A 1998;95:156-61. (Pubitemid 28103923)
46. Watts RG, Huang C, Young MR, Li JJ, Dong Z, Pennie WD, et al. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 1998;17:3493-8. (Pubitemid 29050684)
47. Cho YY, Yao K, Kim HG, Bong SK, Zheng D, Bode AM, et al. Ribosomal S6 kinase 2 is a key regulator in tumor promoter-induced cell transformation. Cancer Res 2007;67:8104-12. (Pubitemid 47395145)
48. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/ AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.